CHRO Overview

Launch of Zelsuvmi: Pelthos Therapeutics Inc. has launched Zelsuvmi (berdazimer) topical gel, the first FDA-approved prescription treatment for molluscum contagiosum, effective for adults and children over one year old, with a notable clinical trial showing nearly 33% complete clearance of lesions in patients.

Company Developments: Following a merger with Channel Therapeutics, Pelthos Therapeutics began trading under the ticker PTHS on the NYSE American exchange, while also implementing a patient support program and expanding its sales team to enhance outreach to physicians treating molluscum infections.

Merger Announcement: Ligand Pharmaceuticals and Pelthos Therapeutics have completed their merger with Channel Therapeutics, launching Pelthos as an independent biopharmaceutical company that will trade under the ticker symbol PTHS starting July 2.

Product Launch Plans: Pelthos is set to commercialize ZELSUVMI, a novel topical gel for treating molluscum contagiosum infections, with plans to launch in July 2025, while also exploring further development of its NaV 1.7 programs for chronic pain treatments.

Merger and Company Launch: Pelthos Therapeutics Inc. has completed a merger, allowing it to operate under its new name and ticker symbol "PTHS" on the NYSE American exchange starting July 2, 2025, while also securing $50.1 million in private placement funding for the launch of its product ZELSUVMI™.

Product Overview: ZELSUVMI™ is an FDA-approved topical gel for treating molluscum contagiosum infections, designed for use by patients at home, marking it as the first prescription medication approved for this condition.

Upcoming Stock Splits: Several companies, including Ainos, Helius Medical Technologies, APi Group, Channel Therapeutics, and SciSparc, are implementing stock splits or reverse stock splits between June 30 and July 4 to either boost share prices or make stocks more accessible to investors.

Purpose of Stock Splits: Stock splits increase the number of shares while maintaining market value, making stocks more affordable, whereas reverse splits reduce share count to meet exchange requirements and avoid delisting.

Reverse Stock Split Announcement: Channel Therapeutics Corporation announced a 10-for-1 reverse stock split to increase its share price and meet NYSE American listing requirements ahead of a merger with LNHC, Inc.

Shareholder Impact: The reverse split will reduce outstanding shares from approximately 6.5 million to about 648,500, but ownership percentages will remain unchanged, and trading under the new name Pelthos Therapeutics Inc. will begin on July 2, 2025.

Reverse Stock Split Announcement: Channel Therapeutics Corp. will execute a 10-for-1 reverse stock split effective July 1, 2025, in conjunction with its merger with Pelthos Therapeutics and a $50.1 million private placement to enhance compliance with NYSE American listing requirements.

Company Focus and Stock Performance: The company is developing non-opioid pain treatments targeting the sodium ion channel NaV1.7, and its stock recently traded at $1.34, reflecting a 14.5% increase on the New York Stock Exchange.